Last reviewed · How we verify
Timolol Maleate Gel
At a glance
| Generic name | Timolol Maleate Gel |
|---|---|
| Sponsor | Auson Pharmaceuticals Inc. |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Beta Adrenergic Antagonist for the Healing of Chronic DFU (PHASE3)
- Evaluate the Safety, Tolerance, and Pharmacokinetic Profiles of Timolol Maleate Gel (PHASE1)
- A Comparative Study of the Pharmacokinetic Profiles of Timolol Maleate Ophthalmic Gel With Timolol Maleate Gel (PHASE1)
- Timolol Maleate Gel for the Treatment of Infantile Hemangioma (PHASE2, PHASE3)
- Efficacy, Safety and Pharmacokinetics of Topical Timolol in Infants With Infantile Hemangioma (IH) (PHASE2)
- Efficacy and Safety of 0.25% Timolol Gel in Enhancing Full Thickness Skin Grafts Healing and Cosmetic Outcomes (PHASE2, PHASE3)
- Efficacy and Safety of 0.25% Timolol Gel in Healing Surgical Open Wounds (PHASE2, PHASE3)
- Timolol Gel for Epistaxis in Hereditary Hemorrhagic Telangiectasia (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Timolol Maleate Gel CI brief — competitive landscape report
- Timolol Maleate Gel updates RSS · CI watch RSS
- Auson Pharmaceuticals Inc. portfolio CI